A citation-based method for searching scientific literature

Jeffrey M Burns, David K Johnson, Edward P Liebmann, Rebecca J Bothwell, Jill K Morris, Eric D Vidoni. Alzheimers Dement 2017
Times Cited: 36







List of co-cited articles
210 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Disclosure of positron emission tomography amyloid imaging results: A preliminary study of safety and tolerability.
Yen Ying Lim, Paul Maruff, Christine Getter, Peter J Snyder. Alzheimers Dement 2016
35
54

Development of a process to disclose amyloid imaging results to cognitively normal older adult research participants.
Kristin Harkins, Pamela Sankar, Reisa Sperling, Joshua D Grill, Robert C Green, Keith A Johnson, Megan Healy, Jason Karlawish. Alzheimers Res Ther 2015
50
50

Comprehension of an Elevated Amyloid Positron Emission Tomography Biomarker Result by Cognitively Normal Older Adults.
Jessica Mozersky, Pamela Sankar, Kristin Harkins, Sara Hachey, Jason Karlawish. JAMA Neurol 2018
30
50

Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Reisa A Sperling, Paul S Aisen, Laurel A Beckett, David A Bennett, Suzanne Craft, Anne M Fagan, Takeshi Iwatsubo, Clifford R Jack, Jeffrey Kaye, Thomas J Montine,[...]. Alzheimers Dement 2011
33

Disclosure of APOE genotype for risk of Alzheimer's disease.
Robert C Green, J Scott Roberts, L Adrienne Cupples, Norman R Relkin, Peter J Whitehouse, Tamsen Brown, Susan LaRusse Eckert, Melissa Butson, A Dessa Sadovnick, Kimberly A Quaid,[...]. N Engl J Med 2009
313
33

Appropriate use criteria for amyloid PET: a report of the Amyloid Imaging Task Force, the Society of Nuclear Medicine and Molecular Imaging, and the Alzheimer's Association.
Keith A Johnson, Satoshi Minoshima, Nicolaas I Bohnen, Kevin J Donohoe, Norman L Foster, Peter Herscovitch, Jason H Karlawish, Christopher C Rowe, Maria C Carrillo, Dean M Hartley,[...]. Alzheimers Dement 2013
274
33

The A4 study: stopping AD before symptoms begin?
Reisa A Sperling, Dorene M Rentz, Keith A Johnson, Jason Karlawish, Michael Donohue, David P Salmon, Paul Aisen. Sci Transl Med 2014
420
33

NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease.
Clifford R Jack, David A Bennett, Kaj Blennow, Maria C Carrillo, Billy Dunn, Samantha Budd Haeberlein, David M Holtzman, William Jagust, Frank Jessen, Jason Karlawish,[...]. Alzheimers Dement 2018
33

Development of a Standardized Approach to Disclosing Amyloid Imaging Research Results in Mild Cognitive Impairment.
Jennifer H Lingler, Meryl A Butters, Amanda L Gentry, Lu Hu, Amanda E Hunsaker, William E Klunk, Meghan K Mattos, Lisa S Parker, J Scott Roberts, Richard Schulz. J Alzheimers Dis 2016
22
45

Amyloid imaging, risk disclosure and Alzheimer's disease: ethical and practical issues.
J Scott Roberts, Laura B Dunn, Gil D Rabinovici. Neurodegener Dis Manag 2013
31
32

Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review.
Arno de Wilde, Marieke M van Buchem, René H J Otten, Femke Bouwman, Andrew Stephens, Frederik Barkhof, Philip Scheltens, Wiesje M van der Flier. Alzheimers Res Ther 2018
19
47

Cognitively unimpaired adults' reactions to disclosure of amyloid PET scan results.
Emily A Largent, Kristin Harkins, Christopher H van Dyck, Sara Hachey, Pamela Sankar, Jason Karlawish. PLoS One 2020
17
52

Disclosure of amyloid imaging results to research participants: has the time come?
Jennifer H Lingler, William E Klunk. Alzheimers Dement 2013
29
27

Communicating mild cognitive impairment diagnoses with and without amyloid imaging.
Joshua D Grill, Liana G Apostolova, Szofia Bullain, Jeffrey M Burns, Chelsea G Cox, Malcolm Dick, Dean Hartley, Claudia Kawas, Sarah Kremen, Jennifer Lingler,[...]. Alzheimers Res Ther 2017
29
27

Attitudes of Research Participants and the General Public Regarding Disclosure of Alzheimer Disease Research Results.
Jonathan Gooblar, Catherine M Roe, Natalie J Selsor, Matthew J Gabel, John C Morris. JAMA Neurol 2015
19
42

A Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status Disclosure.
B R Ott, M A Pelosi, G Tremont, P J Snyder. Alzheimers Dement (N Y) 2016
15
53

Should we disclose amyloid imaging results to cognitively normal individuals?
Joshua D Grill, David K Johnson, Jeffrey M Burns. Neurodegener Dis Manag 2013
23
34

Psychological, behavioral and social effects of disclosing Alzheimer's disease biomarkers to research participants: a systematic review.
S A S A Bemelmans, K Tromp, E M Bunnik, R J Milne, S Badger, C Brayne, M H Schermer, E Richard. Alzheimers Res Ther 2016
31
25


The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Guy M McKhann, David S Knopman, Howard Chertkow, Bradley T Hyman, Clifford R Jack, Claudia H Kawas, William E Klunk, Walter J Koroshetz, Jennifer J Manly, Richard Mayeux,[...]. Alzheimers Dement 2011
19


Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria.
Bruno Dubois, Harald Hampel, Howard H Feldman, Philip Scheltens, Paul Aisen, Sandrine Andrieu, Hovagim Bakardjian, Habib Benali, Lars Bertram, Kaj Blennow,[...]. Alzheimers Dement 2016
658
19

Patient and caregiver reactions to clinical amyloid imaging.
Joshua D Grill, Chelsea G Cox, Sarah Kremen, Mario F Mendez, Edmond Teng, Jill Shapira, John M Ringman, Liana G Apostolova. Alzheimers Dement 2017
19
36

The psychological impact of disclosing amyloid status to Japanese elderly: a preliminary study on asymptomatic patients with subjective cognitive decline.
Taisei Wake, Hajime Tabuchi, Kei Funaki, Daisuke Ito, Bun Yamagata, Takahito Yoshizaki, Masashi Kameyama, Tadaki Nakahara, Koji Murakami, Masahiro Jinzaki,[...]. Int Psychogeriatr 2018
18
38

Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.
Christopher M Clark, Michael J Pontecorvo, Thomas G Beach, Barry J Bedell, R Edward Coleman, P Murali Doraiswamy, Adam S Fleisher, Eric M Reiman, Marwan N Sabbagh, Carl H Sadowsky,[...]. Lancet Neurol 2012
478
16

Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trials.
Scott Y H Kim, Jason Karlawish, Benjamin E Berkman. Neurology 2015
27
22

The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease.
Marilyn S Albert, Steven T DeKosky, Dennis Dickson, Bruno Dubois, Howard H Feldman, Nick C Fox, Anthony Gamst, David M Holtzman, William J Jagust, Ronald C Petersen,[...]. Alzheimers Dement 2011
16

Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit.
José L Molinuevo, Jordi Cami, Xavier Carné, Maria C Carrillo, Jean Georges, Maria B Isaac, Zaven Khachaturian, Scott Y H Kim, John C Morris, Florence Pasquier,[...]. Alzheimers Dement 2016
28
21

Health behavior changes after genetic risk assessment for Alzheimer disease: The REVEAL Study.
Serena Chao, J Scott Roberts, Theresa M Marteau, Rebecca Silliman, L Adrienne Cupples, Robert C Green. Alzheimer Dis Assoc Disord 2008
156
16

Reactions to learning a "not elevated" amyloid PET result in a preclinical Alzheimer's disease trial.
Joshua D Grill, Chelsea G Cox, Kristin Harkins, Jason Karlawish. Alzheimers Res Ther 2018
10
60

Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment.
Joshua D Grill, Rema Raman, Karin Ernstrom, David L Sultzer, Jeffrey M Burns, Michael C Donohue, Keith A Johnson, Paul S Aisen, Reisa A Sperling, Jason Karlawish. JAMA Neurol 2020
12
50

Using AD biomarker research results for clinical care: a survey of ADNI investigators.
Melanie B Shulman, Kristin Harkins, Robert C Green, Jason Karlawish. Neurology 2013
27
18

Clinical use of amyloid-positron emission tomography neuroimaging: Practical and bioethical considerations.
Michael M Witte, Norman L Foster, Adam S Fleisher, Monique M Williams, Kimberly Quaid, Michael Wasserman, Gail Hunt, J Scott Roberts, Gil D Rabinovici, James L Levenson,[...]. Alzheimers Dement (Amst) 2015
23
21

Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.
Michael C Donohue, Reisa A Sperling, Ronald Petersen, Chung-Kai Sun, Michael W Weiner, Paul S Aisen. JAMA 2017
187
13

Public perceptions of presymptomatic testing for Alzheimer disease.
Richard J Caselli, Jessica Langbaum, Gary E Marchant, Rachel A Lindor, Katherine S Hunt, Bruce R Henslin, Amylou C Dueck, Jason S Robert. Mayo Clin Proc 2014
32
15

Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials.
Joshua D Grill, Yan Zhou, David Elashoff, Jason Karlawish. Neurobiol Aging 2016
20
25

Clinical and biomarker changes in dominantly inherited Alzheimer's disease.
Randall J Bateman, Chengjie Xiong, Tammie L S Benzinger, Anne M Fagan, Alison Goate, Nick C Fox, Daniel S Marcus, Nigel J Cairns, Xianyun Xie, Tyler M Blazey,[...]. N Engl J Med 2012
13

Amyloid imaging in cognitively normal individuals, at-risk populations and preclinical Alzheimer's disease.
Gaël Chételat, Renaud La Joie, Nicolas Villain, Audrey Perrotin, Vincent de La Sayette, Francis Eustache, Rik Vandenberghe. Neuroimage Clin 2013
194
13

Alzheimer's disease: the amyloid cascade hypothesis.
J A Hardy, G A Higgins. Science 1992
13

Amnestic MCI patients' experiences after disclosure of their amyloid PET result in a research context.
Gwendolien Vanderschaeghe, Jolien Schaeverbeke, Rose Bruffaerts, Rik Vandenberghe, Kris Dierickx. Alzheimers Res Ther 2017
13
38

Dementia specialists and early adoption of amyloid imaging.
Eran P Klein, Jeffrey Kaye. J Alzheimers Dis 2013
12
33

Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease.
Elizabeth M Wikler, Robert J Blendon, John M Benson. Alzheimers Res Ther 2013
27
14

Clinical Utility of Amyloid PET Imaging in the Differential Diagnosis of Atypical Dementias and Its Impact on Caregivers.
Mohamed Reda Bensaïdane, Jean-Mathieu Beauregard, Stéphane Poulin, François-Alexandre Buteau, Jean Guimond, David Bergeron, Louis Verret, Marie-Pierre Fortin, Michèle Houde, Rémi W Bouchard,[...]. J Alzheimers Dis 2016
35
11

Augmenting Amyloid PET Interpretations With Quantitative Information Improves Consistency of Early Amyloid Detection.
Nicholas R Harn, Suzanne L Hunt, Jacqueline Hill, Eric Vidoni, Mark Perry, Jeffrey M Burns. Clin Nucl Med 2017
20
20

Effect of knowledge of APOE genotype on subjective and objective memory performance in healthy older adults.
Tara T Lineweaver, Mark W Bondi, Douglas Galasko, David P Salmon. Am J Psychiatry 2014
58
11

Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B.
William E Klunk, Henry Engler, Agneta Nordberg, Yanming Wang, Gunnar Blomqvist, Daniel P Holt, Mats Bergström, Irina Savitcheva, Guo-feng Huang, Sergio Estrada,[...]. Ann Neurol 2004
11

A conceptual framework for research on subjective cognitive decline in preclinical Alzheimer's disease.
Frank Jessen, Rebecca E Amariglio, Martin van Boxtel, Monique Breteler, Mathieu Ceccaldi, Gaël Chételat, Bruno Dubois, Carole Dufouil, Kathryn A Ellis, Wiesje M van der Flier,[...]. Alzheimers Dement 2014
993
11

Desire for predictive testing for Alzheimer's disease and impact on advance care planning: a cross-sectional study.
Meera Sheffrin, Irena Stijacic Cenzer, Michael A Steinman. Alzheimers Res Ther 2016
10
40


Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: phase 3 study.
Osama Sabri, Marwan N Sabbagh, John Seibyl, Henryk Barthel, Hiroyasu Akatsu, Yasuomi Ouchi, Kohei Senda, Shigeo Murayama, Kenji Ishii, Masaki Takao,[...]. Alzheimers Dement 2015
241
11


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.